


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (withdrawn): A compound of the formula



in which

X is an oxygen atom,

R¹ is a hydrogen atom,

R² is a fluorine, chlorine or bromine atom or a cyano group,

R³ is a phenyl group or a phenyl group which is monosubstituted by a fluorine, chlorine, bromine or iodine atom or by a C₁₋₃-alkoxy group, where the abovementioned unsubstituted and the monosubstituted phenyl groups may additionally be substituted in the 3- or 4-position

by a fluorine, chlorine or bromine atom,

by a cyano group,

by a C₁₋₃-alkoxy or C₁₋₂-alkyl-carbonyl-amino group,

by a cyano-C₁₋₃-alkyl, carboxy-C₁₋₃-alkyl, carboxy-C₁₋₄-alkoxy, carboxy-C₁₋₃-alkylamino, carboxy-C₁₋₃-alkyl-N-(C₁₋₃-alkyl)-amino, C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkyl, C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkoxy, C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkylamino, C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkyl-N-(C₁₋₃-alkyl)-amino, amino-C₁₋₃-alkyl, amino-carbonyl-C₁₋₃-alkyl, (C₁₋₂-alkylamino)-carbonyl-C₁₋₃-alkyl, di-(C₁₋₂-alkyl)-amino-carbonyl-C₁₋₃-alkyl, (C₁₋₂-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (C₁₋₄-alkoxy-carbonyl)-amino-C₁₋₃-alkyl, (C₃₋₆-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (phenyl-carbonyl)-amino-C₁₋₃-alkyl, (C₃₋₆-cycloalkyl-carbonyl)-amino-C₁₋₃-alkyl, (C₃₋₆-cycloalkyl-C₁₋₃-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (thiophen-2-yl-carbonyl)-amino-C₁₋₃-alkyl, (furan-2-yl-carbonyl)-amino-C₁₋₃-alkyl, (phenyl-C₁₋₃-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (2-(C₁₋₄-alkoxy)-benzoyl-carbonyl)-amino-C₁₋₃-alkyl, (pyridin-2-yl-carbonyl)-amino-C₁₋₃-alkyl, (pyridin-3-yl-carbonyl)-amino-C₁₋₃-alkyl-, (pyridin-4-yl-carbonyl)-amino-C₁₋₃-alkyl- or C₁₋₃-alkyl-piperazin-1-yl-carbonyl-C₁₋₃-alkyl group,

by a carboxy-C₂₋₃-alkenyl, aminocarbonyl-C₂₋₃-alkenyl, (C₁₋₃-alkylamino)-carbonyl-C₂₋₃-alkenyl, di-(C₁₋₃-alkyl)-amino-carbonyl-C₂₋₃-alkenyl or C₁₋₄-alkoxy-carbonyl-C₂₋₃-alkenyl group,


where the substituents may be identical or different,

R⁴ is a phenyl group or a phenyl group which is monosubstituted

by a C₁₋₃-alkyl group which is terminally substituted by an amino, guanidino, mono- or di-(C₁₋₂-alkyl)-amino-, N-[ω-di-(C₁₋₃-alkyl)-amino-C₂₋₃-alkyl]-N-(C₁₋₃-alkyl)-amino, N-methyl-(C₃₋₄-alkyl)-amino, N-(C₁₋₃-alkyl)-N-benzylamino, N-(C₁₋₄-alkoxycarbonyl)-amino, N-(C₁₋₄-alkoxycarbonyl)-C₁₋₄-alkylamino, 4-(C₁₋₃-alkyl)-piperazin-1-yl, imidazol-1-yl, pyrrolidin-1-yl, azetidin-1-yl, morpholin-4-yl, piperazin-1-yl, thiomorpholin-4-yl group,

by a di-(C₁₋₃-alkyl)-amino-(C₁₋₃-alkyl)-sulphonyl, 2-[di-(C₁₋₃-alkyl)-amino]-ethoxy, 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl, {ω-[di-(C₁₋₃-alkyl)-amino]-(C₂₋₃-alkyl)}-N-(C₁₋₃-alkyl)-amino-carbonyl, 1-(C₁₋₃-alkyl)imidazol-2-yl, (C₁₋₃-alkyl)-sulphonyl group, or

by a group of the formula



in which

R⁷ is a C₁₋₂-alkyl, C₁₋₂-alkyl-carbonyl, di-(C₁₋₂-alkyl)-amino-carbonyl-C₁₋₃-alkyl or C₁₋₃-alkylsulphonyl group and

R⁸ is C₁₋₃-alkyl, ω-[di-(C₁₋₂-alkyl)-amino]-C₂₋₃-alkyl, ω-[mono-(C₁₋₂-alkyl)-amino]-C₂₋₃-alkyl group, or

a (C₁₋₃-alkyl)-carbonyl, (C₄₋₆-alkyl)-carbonyl or carbonyl-(C₁₋₃-alkyl) group which is terminally substituted by a di-(C₁₋₂-alkyl)-amino, piperazin-1-yl or 4-(C₁₋₃-alkyl)-piperazin-1-yl group,

where all dialkylamino groups present in the radical R⁴ may also be present in quaternized form, for example as an N-methyl-(N,N-dialkyl)-ammonium group, where the counterion is preferably selected from the group consisting of iodide, chloride, bromide, methylsulphonate, para-toluenesulphonate and trifluoroacetate,

R⁵ is a hydrogen atom and

R⁶ is a hydrogen atom,

where the abovementioned alkyl groups include linear and branched alkyl groups in which additionally one to 3 hydrogen atoms may be replaced by fluorine atoms,

where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical or may be present in the form of a prodrug radical, for example in the form of a group which can be converted in vivo into a carboxyl group or in the form of a group which can be converted in vivo into an imino or amino group,

and its tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof.

Claim 2 (withdrawn): A compound of the formula I according to Claim 1 in which

X, R¹, R², R⁴, R⁵ and R⁶ are as defined in Claim 1 and

R³ is a phenyl group which is substituted

by a C₁₋₂-alkyl-carbonyl-amino group,

by a carboxy-C₁₋₃-alkyl, carboxy-C₁₋₄-alkoxy, C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkyl, C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkoxy, aminocarbonyl-C₁₋₃-alkyl, (C₁₋₂-alkylamino)-carbonyl-C₁₋₃-alkyl, di-(C₁₋₂-alkyl)-aminocarbonyl-C₁₋₃-alkyl, (C₁₋₂-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (C₁₋₄-alkoxy-carbonyl)-amino-C₁₋₃-alkyl, (phenyl-carbonyl)-amino-C₁₋₃-alkyl, (C₃₋₆-cycloalkyl-carbonyl)-amino-C₁₋₃-alkyl, (C₃₋₆-cycloalkyl-C₁₋₃-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (thiophen-2-yl-carbonyl)-amino-C₁₋₃-alkyl, (furan-2-yl-carbonyl)-amino-C₁₋₃-alkyl, (phenyl-C₁₋₃-alkyl-carbonyl)-amino-C₁₋₃-alkyl, (2-(C₁₋₄-alkoxy)-benzoyl-carbonyl)-amino-C₁₋₃-alkyl, (pyridin-2-yl-carbonyl)-amino-C₁₋₃-alkyl, (pyridin-3-yl-carbonyl)-amino-C₁₋₃-alkyl, (pyridin-4-yl-carbonyl)-amino-C₁₋₃-alkyl or C₁₋₃-alkyl-piperazin-1-yl-carbonyl-C₁₋₃-alkyl group,

by an aminocarbonyl-C₂₋₃-alkenyl, (C₁₋₃-alkylamino)-carbonyl-C₂₋₃-alkenyl, di-(C₁₋₃-alkyl)-amino-carbonyl-C₂₋₃-alkenyl or C₁₋₄-alkoxy-carbonyl-C₂₋₃-alkenyl group.

Claim 3 (withdrawn): A compound of the formula I according to Claim 1 in which

X, R¹, R², R⁴, R⁵ and R⁶ are as defined in Claim 1 and

R³ is a phenyl group substituted by a carboxy-C₁₋₃-alkyl or C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkyl group.

Claim 4 (withdrawn): A compound of the formula I according to any of Claims 1 to 3, in which

X, R¹, R³, R⁴, R⁵ and R⁶ are as defined in any of Claims 1 to 3 and

R² is a fluorine or chlorine atom.

Claim 5 (withdrawn): A compound of the formula I according to Claim 1, selected from the following group:

(a) 3-Z-[1-(4-dimethylaminomethyl-anilino)-1-(3-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone

(b) 3-Z-[1-(4-dimethylaminomethyl-anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(c) 3-Z-[1-(4-dimethylaminomethyl-anilino)-1-(3-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(d) 3-Z-[1-(4-(N-(4-methylpiperazin-1-yl)methylcarbonyl)-N-methylamino)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(e) 3-Z-[1-(4-(N-(2-dimethylaminoethyl)-N-methylsulphonylamino)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(f) 3-Z-[1-(4-(N-(3-dimethylaminopropyl)-N-acetylamino)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(g) 3-Z-[1-(4-(1-methylimidazol-2-yl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(h) 3-Z-[1-(4-(N-(dimethylaminomethylcarbonyl)-N-methylamino)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(i) 3-Z-[1-(4-(N-(2-dimethylaminoethylcarbonyl)-N-methylamino)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(j) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(k) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(l) 3-Z-[1-(4-(2-dimethylaminoethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone

(m) 3-Z-[1-(4-dimethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone

(n) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone

(o) 3-Z-[1-(4-(pyrrolidin-1-ylmethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone

(p) 3-Z-[1-(4-(dimethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone

(q) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)-methylene]-6-bromo-2-indolinone

and their salts.

Claim 6 (withdrawn): A physiologically acceptable salt of a compound according to any one of Claims 1, 2, 3 or 5.

Claim 7 (withdrawn): A physiologically acceptable salt of a compound according to Claim 4.

Claim 8 (withdrawn): A medicament comprising a compound of the formula I according to any one of Claims 1, 2, 3 or 5, and one or more inert carrier materials and/or diluents.

Claim 9 (withdrawn): A medicament, comprising a compound of the formula I according to Claim 4, and one or more inert carrier materials and/or diluents.

Claim 10 (withdrawn): A medicament, comprising a physiologically acceptable salt according to Claim 6, and one or more inert carrier materials and/or diluents.

Claim 11 (withdrawn): A medicament, comprising a physiologically acceptable salt according to Claim 7, and one or more inert carrier materials and/or diluents.


Claim 12 (withdrawn): A method for treating excessive or abnormal cell proliferation comprising administering a compound of the formula I according to any one of Claims 1, 2, 3, or 5.

Claim 13 (withdrawn): A method for treating excessive or abnormal cell proliferation comprising administering a compound of the formula I according to Claim 4.

Claim 14 (withdrawn): A method for treating excessive or abnormal cell proliferation comprising administering a physiologically acceptable salt according to Claim 6.

Claim 15 (withdrawn): A method for treating excessive or abnormal cell proliferation comprising administering a physiologically acceptable salt according to Claim 7

Claim 16 (new): A compound of the formula



in which

X is an oxygen atom,

R¹ is a hydrogen atom,

R² is a fluorine, chlorine or bromine atom or a cyano group,


R³ is a phenyl group which is substituted by a carboxy-C₁₋₃-alkyl or C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkyl group

R⁴ is a phenyl group which is monosubstituted

by a C₁₋₃-alkyl group which is terminally substituted by di-(C₁₋₂-alkyl)-amino-,
imidazol-1-yl, pyrrolidin-1-yl,

1-(C₁₋₃-alkyl)imidazol-2-yl, or

by a group of the formula



in which

R⁷ is a C₁₋₂-alkyl, C₁₋₂-alkyl-carbonyl, or C₁₋₃-alkylsulphonyl group and

R⁸ is ω-[di-(C₁₋₂-alkyl)-amino]-C₂₋₃-alkyl, or

a (C₁₋₃-alkyl)-carbonyl group which is terminally substituted by a di-(C₁₋₂-alkyl)-amino, piperazin-1-yl or 4-(C₁₋₃-alkyl)-piperazin-1-yl group,

where all dialkylamino groups present in the radical R^4 may also be present in quaternized form, for example as an N-methyl-(N,N-dialkyl)-ammonium group, where the counterion is preferably selected from the group consisting of iodide, chloride, bromide, methylsulphonate, para-toluenesulphonate and trifluoroacetate,

R^5 is a hydrogen atom and

R^6 is a hydrogen atom,

where the abovementioned alkyl groups include linear and branched alkyl groups in which additionally one to 3 hydrogen atoms may be replaced by fluorine atoms,

where additionally a carboxyl, amino or imino group present may be substituted by an in vivo cleavable radical or may be present in the form of a prodrug radical, for example in the form of a group which can be converted in vivo into a carboxyl group or in the form of a group which can be converted in vivo into an imino or amino group,

or a salt thereof.

Claim 17 (new): A compound of the formula I according to Claim 16, selected from the following group:

(a) 3-Z-[1-(4-dimethylaminomethyl)anilino]-1-(3-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone

(b) 3-Z-[1-(4-dimethylaminomethyl)anilino]-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(c) 3-Z-[1-(4-dimethylaminomethyl)anilino]-1-(3-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(d) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

(e) 3-Z-[1-(4-(2-dimethylaminoethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone

(f) 3-Z-[1-(4-dimethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone


(g) 3-Z-[1-(4-(dimethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-bromo-2-indolinone

(h) 3-Z-[1-(4-(diethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)-methylene]-6-bromo-2-indolinone,
and

(i) 3-Z-[1-(4-dimethylaminomethyl)anilino)-1-(4-(2-ethoxycarbonyl)phenyl)methylene]-6-fluoro-2-indolinone

or a salt of any of the above recited compounds.

Claim 18 (new): The compound of formula I according to claim 17



3-Z-[1-(4-dimethylaminomethyl)anilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

or a salt thereof.

Claim 19 (new): A compound have the following formula and name:

1-acetyl-6-fluoro-2-indolinone

Application No. 10/625,101
Amdt dated December 2, 2005
Reply to Office action of October 28, 2005

